Halozyme, is a biopharmaceutical company which provides innovative and disruptive solutions for novel and well-established therapies. Halozyme with its world class technology have partnered with leading global players to improve patient’s treatment outcomes.
Halozyme’s ENHANZE technology:
Halozyme’s ENHANZE drug delivery technology based on the company’s proprietary recombinant human hyaluronidase enzyme rHuPH20 will help reduce treatment burden of other drugs for patients as it will facilitate the subcutaneous administration of injected drugs and fluids. rHuPH20 degrades hyaluronic glycosaminoglycan (HA), which resists flow of bulk fluid into the subcutaneous space thereby acting as a limiting factor for large volume SC drug delivery, dispersion, and absorption.
- Reduced Treatment Burden and Healthcare Costs
- Potential for Competitive Differentiation
- Potential to Combine Two Therapeutic 3 Antibodies in Single Injection
- Facilitating Higher Injection Volume, Potential to Extend Dosing Interval
- Potential for New Intellectual Property for Co-formulations
Halozyme Attractive Pipeline
|Company||Targets (N)||Product Disclosed||Therapy Area||Indication||Phase|
|Roche||12||TECENTRIQ (atezolizumab)||Oncology||Phase 3|
Halozyme Therapeutics Key Updates to note
On October 6, 2020, Halozyme Therapeutics (NASDAQ:HALO) and argenx (NASDAQ:ARGX) have expanded their existing global collaboration and license agreement that was signed in February 2019. Under the expanded deal, argenx gained the ability to exclusively access Halozyme’s ENHANZE drug delivery technology for three additional targets upon nomination for a total of up to six targets under the existing and newly expanded collaboration. To date, argenx has nominated two targets including the human neonatal Fc receptor FcRn and complement component C2.
Argenx is making rapid progress in the clinic with multiple programs and indications utilizing ENHANZE technology
- Collaboration signed with Halozyme in February 2019
- Phase 2 study in CIDP initiated Within 14 Months
- Bridging strategy for efgartigimod in Myasthenia Gravis using ENHANZE to be discussed with FDA in Q4 2020
|Atezolizumab (Tecentriq) using ENHANZE – (IMscin001) Non-small cell lung cancer (NSCLC)||Phase 1b||Phase 1b data presented at ESMO 2020 noted treatment was well tolerated.|
|DARZALEX (Daratumumab) using ENHANZE Amyloidosis||sNDA Filing||sBLA filing announced September 10, 2020.|
|ARGX-117 Autoimmune diseases||Phase 1||Phase 1 trial to commence 3Q 2020.|
|Subcutaneous Pertuzumab And Trastuzumab HER2-positive early breast cancer||Approved||FDA Approval announced June 29, 2020.|
|DARZALEX (Daratumumab) using ENHANZE Multiple myeloma||Approved||FDA Approval announced May 1, 2020.|
|PEGPH20 and atezolizumab Cholangiocarcinoma||Phase 1b||Phase 1b trial ongoing. 42/70 patients have enrolled as of December 2018.|
|HALO-301 Pancreatic cancer||Phase 3||Phase 3 data November 4, 2019 did not meet primary endpoint.|